Results 51 to 60 of about 1,028,816 (310)

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Fit manufacturing; integrated model of manufacturing strategies

Procedia Manufacturing, 2018
Abstract Manufacturing sector is an essential ingredient to accelerate economic growth of the country. Recent advancements in globalization and technology affect manufacturing systems. By applying manufacturing strategies, manufacturing sector is strategizing to enhance their business performance.
Raghed Ibrahim Esmaeel, Norhayati Zakuan, Noriza Mohd Jamal, Hamed Taherdoost   +3 more
openaire   +1 more source

Environmental scanning strategy of manufacturing companies in Southwestern Nigeria [PDF]

In this paper, we examine the environmental scanning strategy of manufacturing companies in Southwestern Nigeria against the background that manufacturing companies in Nigeria exist in a challenging environment characterised by high import dependency ...
Adebowale, B. O., Egbetokun, A. A., Olamade, O. O., Oyebisi, T. O.   +3 more
core   +1 more source

The impact of an innovative human resource function on firm performance: the moderating role of financing strategy [PDF]

, 2004
The current study examined the impact of the human resource function and financing strategy on the financial performance of 104 UK manufacturing firms.
Dawson, Jeremy, Knight-Turvey, Neal, Neal, Andrew, West, Michael A.   +3 more
core  

Laser Additive Manufacturing of High-Strength Aluminum Alloys: Challenges and Strategies [PDF]

, 2022
Som Dixit, Shunyu Liu
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. [PDF]

Emerg Microbes Infect, 2023
Zeng J, Li Y, Jiang L, Luo L, Wang Y, Wang H, Han X, Zhao J, Gu G, Fang M, Huang Q, Yan J.   +11 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

A Fast Soft Continuum Catheter Robot Manufacturing Strategy Based on Heterogeneous Modular Magnetic Units. [PDF]

Micromachines (Basel), 2023
Zhang T, Li G, Yang X, Ren H, Guo D, Wang H, Chan K, Ye Z, Zhao T, Zhang C, Shang W, Shen Y.   +11 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source